Track the Canadian Junior Mining Market at the speed of AI

Build a portfolio of Canadian junior mining companies on 6ix and get real-time updates the minute they announce something. Discover investor events, company profiles, and news in one place.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
Just now	The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
Just now	Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
Just now	Max Power Mining Closes $25 Million Strategic Investment From Eric Sprott To Accelerate Commercial Evaluation at Lawson Max Power Mining Corp
1h ago	Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform Mach Conferences And Events Ltd.
1h ago	Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform Vanta Holdings Inc.

About

6.92USD+0.10 +1.47%

Closed • Updated at 04:00 GMT+00:00

Market Cap$461.10M

Volume391.0K

Beta0.25

RSI48.97

Health TechnologyPharmaceuticals: Major

Fulcrum Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Recent Videos

$FULC Fulcrum Therapeutics Q1 2026 Earnings | Why Pociredir Could Transform Sickle Cell Treatment

$FULC Fulcrum Therapeutics Q1 2026 Earnings | Why Pociredir Could Transform Sickle Cell Treatment

Apr 28, 2026

Fulcrum Therapeutics (FULC|$538.1M) - 2026 Q1 Earnings Analysis

Fulcrum Therapeutics (FULC|$538.1M) - 2026 Q1 Earnings Analysis

Apr 27, 2026

Fulcrum Therapeutics Inc Naked Put

Fulcrum Therapeutics Inc Naked Put

Apr 16, 2026

Kim Hazen - Chief People Officer at Fulcrum Therapeutics - Episode 113

Kim Hazen - Chief People Officer at Fulcrum Therapeutics - Episode 113

Feb 05, 2026

Community Chat

Ask AI

Try asking